Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arcoxia
2. L 791456
3. L-791456
4. L791456
5. Mk 0663
6. Mk-0663
7. Mk0663
1. 202409-33-4
2. Arcoxia
3. Tauxib
4. Nucoxia
5. Algix
6. Mk-0663
7. 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine
8. Mk-663
9. L-791456
10. Mk 0663
11. 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
12. Mk 663
13. 2,3'-bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-
14. 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
15. Wrx4nfy03r
16. L791456
17. 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine
18. Chebi:6339
19. Chembl416146
20. 2,3'-bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-
21. 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
22. Ncgc00164578-01
23. Etoricoxibe
24. Etropain
25. Torcoxia
26. Etoxib
27. 5-chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
28. Mk-0663;l-791456
29. Dsstox_cid_26457
30. Dsstox_rid_81631
31. Dsstox_gsid_46457
32. Etoricoxib [usan:inn:ban]
33. Kingcox
34. 5-chloro-6'-methyl-3-(4-(methylsulfonyl)-phenyl)-2,3'-bipyridine
35. Etoricoxib [usan]
36. Cas-202409-33-4
37. Sr-05000001486
38. Etoricoxib (usan/inn)
39. Unii-wrx4nfy03r
40. Mk0663
41. Etoricoxibum
42. Etoricoxib- Bio-x
43. Etoricoxib [mi]
44. Etoricoxib [inn]
45. Etoricoxib [mart.]
46. Schembl4680
47. Etoricoxib [who-dd]
48. Gtpl2896
49. Dtxsid3046457
50. Hms2090a05
51. Hms3713p20
52. Hms3885h14
53. Zinc579472
54. Amy30994
55. Bcp06428
56. Ex-a2642
57. Tox21 112206
58. Tox21_112206
59. Bdbm50072064
60. Etoricoxib; Mk-663; Mk-0663
61. Mfcd06797512
62. S4651
63. Akos016010125
64. Tox21_112206_1
65. Ccg-220639
66. Cs-1047
67. Db01628
68. Sb18988
69. Ncgc00164578-02
70. 5ch
71. Ac-29052
72. As-17761
73. Bc164436
74. Etoricoxib 100 Microg/ml In Acetonitrile
75. Hy-15321
76. Db-045133
77. Ft-0602793
78. Ft-0668437
79. D03710
80. Etoricoxib, Vetranal(tm), Analytical Standard
81. Ab01275483-01
82. 409e334
83. A848896
84. L001141
85. Q631202
86. J-013140
87. Sr-05000001486-1
88. Sr-05000001486-2
89. Brd-k54770957-001-01-9
90. Brd-k54770957-001-02-7
91. L-791,456
92. F2173-0490
93. Etoricoxib, United States Pharmacopeia (usp) Reference Standard
94. 5-chloro-3-(4-methanesulfonyl-phenyl)-6''''-methyl-[2,3'''']bipyridinyl
95. 5-chloro-3-(4-methanesulfonyl-phenyl)-6''-methyl-[2,3'']bipyridinyl
96. 5-chloro-3-(4-methanesulfonylphenyl)-2-(6-methylpyridin-3-yl)pyridine
97. 5-chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine
98. 5-chloro-6''-methyl-3-[4-(methylsulfonyl)phenyl]-2,3''-bipyridine
Molecular Weight | 358.8 g/mol |
---|---|
Molecular Formula | C18H15ClN2O2S |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 358.0542766 g/mol |
Monoisotopic Mass | 358.0542766 g/mol |
Topological Polar Surface Area | 68.3 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 514 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).
Cyclooxygenase 2 Inhibitors
A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2. (See all compounds classified as Cyclooxygenase 2 Inhibitors.)
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
M01AH05
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
M - Musculo-skeletal system
M01 - Antiinflammatory and antirheumatic products
M01A - Antiinflammatory and antirheumatic products, non-steroids
M01AH - Coxibs
M01AH05 - Etoricoxib
Absorption
Bioavailability is 100% following oral administration.
Hepatic, primarily via CYP3A4.
Etoricoxib has known human metabolites that include 6-Hydroxymethyletoricoxib and Etoricoxib 1'-N'-oxide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
22 hours
Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.
About the Company : Zeon Pharma Industries India Pvt ltd is an ISO & GMP certified manufacturer of Bulk drugs & Intermediate and also supplies our associate manufacturing plant API / Semi finish form...
About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in th...
About the Company : Emay Pharmaceuticals Pvt Ltd functions as the merchant export division of M/s. Bhavna Laboratories Pvt Ltd. As a GMP-approved API manufacturing company, we boast over three decades...
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
About the Company : Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncolog...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Virupaksha Organics, founded in 2003 by G. Chandra Mouliswar Reddy, is committed to delivering products of the utmost quality to its customers. In a span of less than 20 years, the...
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of expertise in formulation development, manufacturing, and commercialization. Our portfolio...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Etoricoxib Zentiva
Dosage Form : Filmtabl
Dosage Strength : 30mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Etoricoxib Zentiva
Dosage Form : Filmtabl
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Etoricoxib Zentiva
Dosage Form : Filmtabl
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : ETORICOXIB THINKS
Dosage Form : Film-Coated Tablets
Dosage Strength : 60 mg
Packaging : 20 UNITS 60 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : ETORICOXIB THINKS
Dosage Form : Film-Coated Tablets
Dosage Strength : 90 mg
Packaging : 20 UNITS 90 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : Arcoxia
Dosage Form : FILM COATED PILL
Dosage Strength : 60 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Switzerland
Brand Name : Arcoxia
Dosage Form : Filmtabl
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Arcoxia
Dosage Form : FILM COATED PILL
Dosage Strength : 60 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : 28 Acoxxel 30Mg Film-Coated Tablets
Dosage Form : Film Coated Tablet
Dosage Strength : 30 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : Arcoxia 30Mg 28 Tablets Coated Film
Dosage Form : Film Coated Tablet
Dosage Strength : 30 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
34
PharmaCompass offers a list of Etoricoxib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Etoricoxib manufacturer or Etoricoxib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Etoricoxib manufacturer or Etoricoxib supplier.
PharmaCompass also assists you with knowing the Etoricoxib API Price utilized in the formulation of products. Etoricoxib API Price is not always fixed or binding as the Etoricoxib Price is obtained through a variety of data sources. The Etoricoxib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nucoxia manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nucoxia, including repackagers and relabelers. The FDA regulates Nucoxia manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nucoxia API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nucoxia manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nucoxia supplier is an individual or a company that provides Nucoxia active pharmaceutical ingredient (API) or Nucoxia finished formulations upon request. The Nucoxia suppliers may include Nucoxia API manufacturers, exporters, distributors and traders.
click here to find a list of Nucoxia suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nucoxia DMF (Drug Master File) is a document detailing the whole manufacturing process of Nucoxia active pharmaceutical ingredient (API) in detail. Different forms of Nucoxia DMFs exist exist since differing nations have different regulations, such as Nucoxia USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nucoxia DMF submitted to regulatory agencies in the US is known as a USDMF. Nucoxia USDMF includes data on Nucoxia's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nucoxia USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nucoxia suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nucoxia Drug Master File in Korea (Nucoxia KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nucoxia. The MFDS reviews the Nucoxia KDMF as part of the drug registration process and uses the information provided in the Nucoxia KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nucoxia KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nucoxia API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nucoxia suppliers with KDMF on PharmaCompass.
A Nucoxia written confirmation (Nucoxia WC) is an official document issued by a regulatory agency to a Nucoxia manufacturer, verifying that the manufacturing facility of a Nucoxia active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nucoxia APIs or Nucoxia finished pharmaceutical products to another nation, regulatory agencies frequently require a Nucoxia WC (written confirmation) as part of the regulatory process.
click here to find a list of Nucoxia suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nucoxia as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nucoxia API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nucoxia as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nucoxia and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nucoxia NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nucoxia suppliers with NDC on PharmaCompass.
Nucoxia Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nucoxia GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nucoxia GMP manufacturer or Nucoxia GMP API supplier for your needs.
A Nucoxia CoA (Certificate of Analysis) is a formal document that attests to Nucoxia's compliance with Nucoxia specifications and serves as a tool for batch-level quality control.
Nucoxia CoA mostly includes findings from lab analyses of a specific batch. For each Nucoxia CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nucoxia may be tested according to a variety of international standards, such as European Pharmacopoeia (Nucoxia EP), Nucoxia JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nucoxia USP).